Cresco Labs (CRLBF) Cash & Equivalents (2019 - 2026)

Cresco Labs' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $32.3 million for Q1 2026.

• Quarterly Cash & Equivalents changed N/A year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (changed N/A YoY) and the FY2025 annual result came in at $57.9 million, changed N/A from the prior year.
• Cash & Equivalents was $32.3 million for Q1 2026 at Cresco Labs, down from $57.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $226.1 million in Q1 2022 and bottomed at $32.3 million in Q1 2026.
• A 5-year average of $106.4 million and a median of $103.4 million in 2023 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 12.69% in 2022, while the deepest fall reached 12.69% in 2022.
• Cresco Labs' Cash & Equivalents stood at $226.1 million in 2022, then tumbled by 54.26% to $103.4 million in 2023, then rose by 8.57% to $112.3 million in 2024, then tumbled by 48.44% to $57.9 million in 2025, then sank by 44.14% to $32.3 million in 2026.
• Business Quant data shows CRLBF's Cash & Equivalents at $32.3 million in Q1 2026, $57.9 million in Q4 2025, and $112.3 million in Q2 2024.